New drugs for the treatment of complicated intra-abdominal infections in the era of increasing antimicrobial resistance

Ling-Shan Syue, Yen Hsu Chen, Wen-Chien Ko, Po Ren Hsueh

Research output: Contribution to journalShort survey

21 Citations (Scopus)

Abstract

The continuing increase in multidrug-resistant organisms (MDROs) worldwide has created new challenges in treating complicated intra-abdominal infections (cIAIs). A number of novel antimicrobial agents have been developed against resistant pathogens. To target extended-spectrum β-lactamase (ESBL)-producing pathogens, novel β-lactam antibiotics, such as ceftolozane/tazobactam, ceftazidime/avibactam, aztreonam/avibactam, imipenem/relebactam and S-649266, are antimicrobial alternatives for cIAIs. Two new drugs, eravacycline and plazomicin, have activity against Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae, carbapenem-resistant Acinetobacter baumannii and ESBL-producers. New lipoglycopeptides and oxazolidinones provide feasible options against resistant Gram-positive pathogens. These novel antimicrobials may play a role in improving the clinical outcomes of cIAIs caused by MDROs.

Original languageEnglish
Pages (from-to)250-258
Number of pages9
JournalInternational journal of antimicrobial agents
Volume47
Issue number4
DOIs
Publication statusPublished - 2016 Apr 1

Fingerprint

Intraabdominal Infections
Klebsiella pneumoniae
Pharmaceutical Preparations
Oxazolidinones
Aztreonam
Acinetobacter baumannii
Lactams
Carbapenems
Imipenem
Anti-Infective Agents
Anti-Bacterial Agents

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)

Cite this

@article{bfe4791c635c4bb9af3db497816e4666,
title = "New drugs for the treatment of complicated intra-abdominal infections in the era of increasing antimicrobial resistance",
abstract = "The continuing increase in multidrug-resistant organisms (MDROs) worldwide has created new challenges in treating complicated intra-abdominal infections (cIAIs). A number of novel antimicrobial agents have been developed against resistant pathogens. To target extended-spectrum β-lactamase (ESBL)-producing pathogens, novel β-lactam antibiotics, such as ceftolozane/tazobactam, ceftazidime/avibactam, aztreonam/avibactam, imipenem/relebactam and S-649266, are antimicrobial alternatives for cIAIs. Two new drugs, eravacycline and plazomicin, have activity against Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae, carbapenem-resistant Acinetobacter baumannii and ESBL-producers. New lipoglycopeptides and oxazolidinones provide feasible options against resistant Gram-positive pathogens. These novel antimicrobials may play a role in improving the clinical outcomes of cIAIs caused by MDROs.",
author = "Ling-Shan Syue and Chen, {Yen Hsu} and Wen-Chien Ko and Hsueh, {Po Ren}",
year = "2016",
month = "4",
day = "1",
doi = "10.1016/j.ijantimicag.2015.12.021",
language = "English",
volume = "47",
pages = "250--258",
journal = "International Journal of Antimicrobial Agents",
issn = "0924-8579",
publisher = "Elsevier",
number = "4",

}

New drugs for the treatment of complicated intra-abdominal infections in the era of increasing antimicrobial resistance. / Syue, Ling-Shan; Chen, Yen Hsu; Ko, Wen-Chien; Hsueh, Po Ren.

In: International journal of antimicrobial agents, Vol. 47, No. 4, 01.04.2016, p. 250-258.

Research output: Contribution to journalShort survey

TY - JOUR

T1 - New drugs for the treatment of complicated intra-abdominal infections in the era of increasing antimicrobial resistance

AU - Syue, Ling-Shan

AU - Chen, Yen Hsu

AU - Ko, Wen-Chien

AU - Hsueh, Po Ren

PY - 2016/4/1

Y1 - 2016/4/1

N2 - The continuing increase in multidrug-resistant organisms (MDROs) worldwide has created new challenges in treating complicated intra-abdominal infections (cIAIs). A number of novel antimicrobial agents have been developed against resistant pathogens. To target extended-spectrum β-lactamase (ESBL)-producing pathogens, novel β-lactam antibiotics, such as ceftolozane/tazobactam, ceftazidime/avibactam, aztreonam/avibactam, imipenem/relebactam and S-649266, are antimicrobial alternatives for cIAIs. Two new drugs, eravacycline and plazomicin, have activity against Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae, carbapenem-resistant Acinetobacter baumannii and ESBL-producers. New lipoglycopeptides and oxazolidinones provide feasible options against resistant Gram-positive pathogens. These novel antimicrobials may play a role in improving the clinical outcomes of cIAIs caused by MDROs.

AB - The continuing increase in multidrug-resistant organisms (MDROs) worldwide has created new challenges in treating complicated intra-abdominal infections (cIAIs). A number of novel antimicrobial agents have been developed against resistant pathogens. To target extended-spectrum β-lactamase (ESBL)-producing pathogens, novel β-lactam antibiotics, such as ceftolozane/tazobactam, ceftazidime/avibactam, aztreonam/avibactam, imipenem/relebactam and S-649266, are antimicrobial alternatives for cIAIs. Two new drugs, eravacycline and plazomicin, have activity against Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae, carbapenem-resistant Acinetobacter baumannii and ESBL-producers. New lipoglycopeptides and oxazolidinones provide feasible options against resistant Gram-positive pathogens. These novel antimicrobials may play a role in improving the clinical outcomes of cIAIs caused by MDROs.

UR - http://www.scopus.com/inward/record.url?scp=84961226195&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961226195&partnerID=8YFLogxK

U2 - 10.1016/j.ijantimicag.2015.12.021

DO - 10.1016/j.ijantimicag.2015.12.021

M3 - Short survey

VL - 47

SP - 250

EP - 258

JO - International Journal of Antimicrobial Agents

JF - International Journal of Antimicrobial Agents

SN - 0924-8579

IS - 4

ER -